Merck & Co.

6MK.DE

Drug Manufacturers - General · Healthcare

Exchange

Frankfurt Stock Exchange

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Weak

Cash Flow

Exceptional

Stability

Good

Valuation

Good

Dividends

Mixed

Track this stock — start free trial

Winston Score History

The full picture

Merck & Co. is a large American pharmaceutical company that discovers, makes, and sells prescription medicines, vaccines, and animal health products. Its biggest product is Keytruda, a cancer drug used to treat many types of tumors, which has become one of the best-selling medicines in the world. Merck sells to hospitals, doctors, pharmacies, and governments across the healthcare industry.

Merck earns most of its revenue by selling branded prescription drugs directly to healthcare providers and through pharmacy benefit managers, with animal health products adding a smaller but steady income stream. The company operates in over 140 countries and generates roughly $60 billion in annual revenue, with its deep pipeline of drugs under development and strong patent protections acting as key competitive advantages. The biggest risk Merck faces is that Keytruda's core patents begin expiring around 2028, which could sharply reduce revenue unless new drugs in its pipeline successfully reach the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-130.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$8.4B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Merck & Co. is growing revenue at 5% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

73.5%

Premium pricing power — 73.5% gross margin

Profit after running costs

Operating Margin

-2.6%

Losing money on operations — -2.6%

Return on the money invested

ROCE

12.6%

Good — 12.6% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+4.5%

Slow sales growth (+4.5% YoY)

Profit growth

EPS YoY

-80.5%

Earnings shrinking (-80.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

626%

Turns 626% of profit into real cash

Spare cash per sale

FCF Margin

24.1%

Converts sales into free cash efficiently (24.1%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.29

Elevated debt (1.29)

Covers its interest

Interest Cover

7.34x

Adequate interest coverage (7.3x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

121.1x

Expensive — P/E 121.1

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+106.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (121.1 → 14.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.27%

Moderate income — 2.27% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+0.9%

Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial